source
- Cellectis abandons CAR-T programs, shifts focus to in vivo gene editingCellectis announced it will discontinue its donor-derived CAR‑T programs and redirect its efforts toward in vivo gene‑editing medicines. The company said the commercial and clinical landscape for…
- RA Capital backs four biotech rounds in September as Novartis shares tumble after trial setbacksRA Capital Management participated in four biotech financings in September, including Series A rounds for Solstice Oncology and Tectora Therapeutics, as well as co-leading a $56 million round for T…